Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rosetta Genomics Secures Medicare Reimbursement Pricing for miRview(R) mets2

Published: Tuesday, June 26, 2012
Last Updated: Tuesday, June 26, 2012
Bookmark and Share
Pricing commensurate with the assay's clinical value and consistent with other high-value, clinical assays.

Rosetta Genomics Ltd. announced that the designated Medicare Administrative Contractor (MAC) for the Company's miRview(R) mets^2 assay has determined the assay to be reasonable and necessary for the diagnosis of cancers of unknown origin in a specified setting and has established a reimbursement rate for the assay. The coverage decision can be found at the following link: https://www.novitas-solutions.com/bulletins/all/news-06152012.html. The miRview(R) mets2 assay accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary (CUP).

"This is another critical commercial milestone for Rosetta Genomics as equitable reimbursement is one of the key drivers for clinical and commercial adoption of the technology. We are pleased with the coverage and the reimbursement amount that the designated MAC has established. The reimbursement amount is commensurate with the clinical value of miRview(R) mets^2 and is consistent with assays of similarly high clinical value," noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "New tumor specific and molecularly-targeted oncology drugs are driving the need for accurate identification and classification of tumor types in order to optimize treatment and improve patient outcomes. With approximately 180,000-220,000 CUP patients per year in the U.S., this represents a large market opportunity for Rosetta Genomics."

About miRview(R) Products miRview(R) are a series of microRNA-based diagnostic products offered by Rosetta Genomics. miRview(R) mets^2 accurately identifies the primary tumor type in primary and metastatic cancer including Cancer of Unknown Primary (CUP). miRview(R) squamous accurately identifies the squamous subtype of non-small cell lung cancer, which carries an increased risk of severe or fatal internal bleeding and poor response to treatment for certain therapies. miRview(R) meso diagnoses mesothelioma, a cancer connected to asbestos exposure. miRview(R) lung accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. miRview(R) kidney accurately classifies the four most common kidney tumors: Clear Cell Renal Cell Carcinoma (RCC), Papillary RCC, Chromophobe RCC and Oncocytoma. miRview(R) tests are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview(R) mets^2 test, 60,000 from miRview(R) squamous, 60,000 from miRview(R) meso, 54,000 from miRview(R) kidney and more than 1 million patients worldwide from miRview(R) lung. The Company's tests are offered directly by Rosetta Genomics in the U.S., and through distributors around the globe. For more information, please visit www.mirviewdx.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rosetta Genomics Receives Approval from New York State
Company has received approval from the NY State for HEME FISH-based tests for detection of amplifications or rearrangements of DNA in a number of hematologic cancers.
Saturday, June 25, 2016
Rosetta Receives Approval from NY State for Four PCR-Based Assays
BRAF, EGFR, KRAS and NRAS mutation detection assays now available in all 50 states.
Tuesday, May 24, 2016
Rosetta Receives Approval for RosettaGX Reveal™
Company has announced conditional approval status for RosettaGX Reveal™, its novel microRNA classifier for the diagnosis of indeterminate thyroid fine needle aspirate.
Friday, March 04, 2016
Rosetta Receives Approval for Cancer Diagnostic
Conditional approval makes RosettaGX Reveal™ available in all 50 states.
Friday, February 19, 2016
Rosetta Genomics to Acquire PersonalizeDx
Rosetta will gain proprietary tests in prostate, bladder and lung cancer.
Monday, April 13, 2015
Rosetta Genomics and Moffitt Cancer Center Enter into Strategic Alliance
Leverages strengths of both organizations to develop diagnostic assays for important, unmet needs in cancer.
Friday, September 05, 2014
Rosetta Genomics Expands Management Team
Brings extensive track record in leading commercial teams and driving revenues in microRNA, oncology and thyroid diagnostics.
Tuesday, August 26, 2014
Rosetta Genomics, Moffitt Cancer Center Enter mRNA-Based Cancer Diagnostic Agreement
Partnership to advance the development and commercialization of Rosetta's thyroid neoplasia assay.
Tuesday, June 10, 2014
Rosetta Genomics to Receive U.S. Patent for Oncology Therapeutic
Company receives a Notice of Allowance from the USPTO for a patent claiming Mp53-negative cancer patients.
Thursday, February 27, 2014
Rosetta Genomics Appoints Kevin Watson
Recognized expert in healthcare policy and reimbursement to lead payer efforts for Company's line of microRNA diagnostics.
Thursday, February 20, 2014
Rosetta Genomics Executes Credentialing Agreements With Two National Healthcare Preferred Provider Networks
Adds approximately 44 million potential covered lives for the Rosetta Cancer Origin Test.
Monday, September 09, 2013
Study Validating miRview Lung Assay Published in Journal of Molecular Diagnostics
Assay shown to accurately differentiate between the four main types of lung cancer.
Wednesday, July 11, 2012
Rosetta Genomics Announces Compliance with Continued Listing Requirements of The NASDAQ Capital Market
Company is in compliance with the $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market®.
Thursday, June 07, 2012
Rosetta to Raise $2.2 Million in Registered Direct Offering
Company has entered into agreements with investors to purchase an aggregate of 632,057 ordinary shares at a price of $3.50 per share.
Friday, May 18, 2012
Rosetta Announces $1.75 Million Debt Financing and Potential $1.25 Million Licensing Transaction
Pursuant to the terms of the transaction, Rosetta has also agreed to negotiate in good faith a definitive license agreement with a designee of the holders of the debentures.
Friday, January 27, 2012
Scientific News
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
JPK Instruments reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!